This site is intended for healthcare professionals

European Commission approves Opdivo + Yervoy as first-line treatment for unresectable malignant pleural mesothelioma.- BMS

Read time: 1 mins
Last updated:28th Jun 2021
Published:8th Jun 2021
Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM).
Condition: Malignant Mesothelioma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest